BRCA2 and colonic neoplasm: To assess the effects of BRCA2 status on the sensitivity towards TRAIL-R-mediated apoptosis, proliferation assays were performed upon administration of recombinant human TRAIL in parental BRCA2 wild type DLD1 colon cancer cells (termed DLD1), heterozygote BRCA2+/− KO cells (clone termed A9A2) and homozygous BRCA2−/− KO cells (two independently established clones termed A10-1 and A10-3, respectively).